| Abby Jean Jacobs, NP | |
|
725 Welch Rd, Palo Alto, CA 94304-1601 | |
| (650) 497-8000 | |
| Not Available |
| Full Name | Abby Jean Jacobs |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 725 Welch Rd, Palo Alto, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043515414 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 20482 (California) | Primary |
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
Kaiser Health News provides a fresh take on health policy developments with "No, Please, After You!" by Chip Bok.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it has completed patient enrolment for a pivotal Phase 3 registration trial (Study 009) for MoxDuo IR. The comparative study was designed to evaluate analgesic efficacy and safety of MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone, for managing moderate to severe pain in patients who have undergone total knee replacement surgery.
The prostate cancer charter for change from 13 influential European and US prostate cancer patient groups, calls for the disease to be treated with the same level of priority as breast cancer is in women.
Researchers found a higher bacterial diversity in SARS-CoV-2 patient rooms and surfaces in the room, suggesting bacterial diversity may play a role in virus transmission.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes.
› Verified 8 days ago
| Entity Name | Lpch Medical Group Div Of Lucile |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417907940 PECOS PAC ID: 0840298543 Enrollment ID: O20061113000232 |
News Archive
Kaiser Health News provides a fresh take on health policy developments with "No, Please, After You!" by Chip Bok.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it has completed patient enrolment for a pivotal Phase 3 registration trial (Study 009) for MoxDuo IR. The comparative study was designed to evaluate analgesic efficacy and safety of MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone, for managing moderate to severe pain in patients who have undergone total knee replacement surgery.
The prostate cancer charter for change from 13 influential European and US prostate cancer patient groups, calls for the disease to be treated with the same level of priority as breast cancer is in women.
Researchers found a higher bacterial diversity in SARS-CoV-2 patient rooms and surfaces in the room, suggesting bacterial diversity may play a role in virus transmission.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Abby Jean Jacobs, NP 725 Welch Rd, Palo Alto, CA 94304-1601 Ph: (650) 497-8000 | Abby Jean Jacobs, NP 725 Welch Rd, Palo Alto, CA 94304-1601 Ph: (650) 497-8000 |
News Archive
Kaiser Health News provides a fresh take on health policy developments with "No, Please, After You!" by Chip Bok.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it has completed patient enrolment for a pivotal Phase 3 registration trial (Study 009) for MoxDuo IR. The comparative study was designed to evaluate analgesic efficacy and safety of MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone, for managing moderate to severe pain in patients who have undergone total knee replacement surgery.
The prostate cancer charter for change from 13 influential European and US prostate cancer patient groups, calls for the disease to be treated with the same level of priority as breast cancer is in women.
Researchers found a higher bacterial diversity in SARS-CoV-2 patient rooms and surfaces in the room, suggesting bacterial diversity may play a role in virus transmission.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes.
› Verified 8 days ago
Wendy Leigh Adams, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 | |
Mr. Christopher Gerard Gonzales, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3801 Miranda Ave, Emergency Department, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Sarah Davidson, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 212 High St, Palo Alto, CA 94301 Phone: 415-663-5584 | |
Erin Danielle Herse, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-736-7359 Fax: 650-497-8041 | |
Christian Laparan, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 795 El Camino Real, Palo Alto, CA 94301 Phone: 650-853-2977 | |
Theresa V Pittman, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 795 El Camino Real, Palo Alto, CA 94301 Phone: 650-321-4121 | |
Audrey Fong, CPNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 Fax: 650-498-5840 |